HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Voyager Therapeutics (NASDAQ:VYGR) and maintained a $30 price target, as stated by analyst Patrick Trucchio.
July 31, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Voyager Therapeutics and maintained a $30 price target, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $30 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100